Therapeutic Approach For COVID-19 – Clinical Challenges And Implementation
| Autor: | Das Abhichandan, Pathak Upasana, Ahmad Faizan, Naaz Sabiha, Suleman Sharique |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Convalescent plasma Coronavirus disease 2019 (COVID-19) Epidemiology business.industry Economic sector 030106 microbiology Applied Microbiology and Biotechnology law.invention 03 medical and health sciences Therapeutic approach 030104 developmental biology Infectious Diseases Randomized controlled trial law Multinational corporation Family medicine Pandemic Medicine business China Biotechnology |
| Zdroj: | Bionatura. 5:1404-1409 |
| ISSN: | 1390-9355 1390-9347 |
| DOI: | 10.21931/rb/2020.05.04.22 |
| Popis: | SAR-CoV-2 originated from China with first case reporting from Wuhan, has been declared as pandemic by WHO on March 11 2020, which has affected millions of people around the globe with 213 countries and territories infected worldwide. It has caused the death of around 0.6 million individuals with no specific or promising vaccines or treatment available until now to prevent COVID 19, which has been approved; this has led the world to a global crisis not only on the health front but also affected the economic sectors. Researchers across the globe are working around the clock with their level best to discover promising therapeutic approaches for COVID 19, but till now for the treatment, only 3 therapeutics have been approved, including dexamethasone in U.K. and Japan, Avigan in Russia, Italy, and China and remdesivir in Japan and Australia; also convalescent plasma therapy is seen to be effective in critical cases of COVID-19, however, there are limitations with the use of this plasma therapy like the time point of treatment, optimal dose as the dose may vary with number of patients the particular therapeutic effects of convalescent plasma therapy will be further explored in randomized clinical trials. Several complete multinational studies are investigating alternative therapies. More than 100 countries entered a cooperation to evaluate applicants for high-profile COVID-19 diagnosis with this most massive WHO's cooperation. According to WHO's information, there are 28 vaccine candidates under clinical evaluation, with 6 of them entering phase 3. This review emphasizes the allopathic approaches along with the Chinese herbal medicine for the prevention of COVID-19. This paper also includes a brief discussion on the vaccine and nutritional supplements. Keywords: SAR-CoV-2, COVID-19, therapeutics, drugs, vaccines |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|